Skip to main content
LAVA Therapeutics NV logo

LAVA Therapeutics NV — Investor Relations & Filings

Ticker · LVTX ISIN · NL0015000AG6 LEI · 724500HENIO3AVE6KA30 US Manufacturing
Open in API
Filings indexed 160 across all filing types
Latest filing 2025-12-16 Regulatory Filings
Country NL Netherlands
Listing US LVTX

About LAVA Therapeutics NV

https://www.lavatherapeutics.com/

LAVA Therapeutics NV is a clinical-stage immuno-oncology company that develops cancer therapies through its proprietary Gammabody® platform. This platform generates bispecific antibodies designed to engage and activate Vγ9Vδ2 (Vgamma9 Vdelta2) T cells, a unique and abundant subset of immune effector cells. The therapeutic approach aims to direct these T cells to tumors, leading to the selective killing of cancer cells and the stimulation of a broader, durable anti-tumor immune response. The company's focus is on creating treatments that complement natural tumor recognition and have the potential to enhance patient survival across various malignancies.

Recent filings

Filing Released Lang Actions
15-12G
Regulatory Filings Classification · 100% confidence The document is a Form 15 filed with the SEC, titled 'Certification and Notice of Termination of Registration under Section 12(g) of the Securities Exchange Act of 1934 or Suspension of Duty to File Reports under Sections 13 and 15(d)'. It is a regulatory filing notifying the termination or suspension of reporting obligations. The document is short (1833 characters) and serves as a notice rather than a full report. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory notices and certifications.
2025-12-16 English
Regulatory Filings 2025
Regulatory Filings
2025-11-21 English
S-8 POS
Transaction in Own Shares Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to Form S-8 Registration Statements filed with the SEC. It discusses deregistration of securities related to stock option plans and employee stock purchase plans, and details the termination of offerings under these registration statements. The document is a regulatory filing related to securities registration and deregistration, not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive information about the deregistration and tender offer completion. The Form S-8 is a registration statement for securities, and this is a post-effective amendment to that registration. Therefore, the document fits best under Transaction in Own Shares (POS) category, as it relates to the termination of securities offerings and share tendering under stock plans.
2025-11-21 English
S-8 POS
Transaction in Own Shares Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to Form S-8 Registration Statements filed with the SEC. It discusses deregistration of securities related to stock option plans and employee stock purchase plans, and details about a purchase agreement and tender offer. Form S-8 is used for securities registration related to employee benefit plans. The document is a regulatory filing related to securities registration and deregistration, not a financial report, earnings release, or other report types. It is not a report publication announcement since it contains substantive amendment information. Therefore, the document fits best under Transaction in Own Shares (POS) category, which covers share repurchase/issuance and related filings.
2025-11-21 English
SC 14D9/A
Merger & Acquisition Classification · 100% confidence The document is a Schedule 14D-9 Amendment No. 6 filed with the SEC, which is a Solicitation/Recommendation Statement related to a tender offer under Section 14(d)(4) of the Securities Exchange Act of 1934. It discusses updates to the tender offer process, including the expiration of the Subsequent Offering Period, acceptance of shares, and the delisting of the company's shares from Nasdaq. The document also references a Form 25 filing notifying the removal from listing and the suspension of trading. This type of filing is specifically related to merger and acquisition tender offer communications and amendments thereto. Therefore, it fits the category of Merger & Acquisition filings (MA). The document is not a full merger proxy statement or a takeover bid announcement alone but an amendment to a solicitation/recommendation statement related to a tender offer, which is classified under MA.
2025-11-21 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 21, 2025, by LAVA Therapeutics N.V. It details the completion of an acquisition (purchase of shares by XOMA Royalty Corporation), the commencement and expiration of a subsequent offering period, notification of delisting from Nasdaq, and changes in executive officers. The document includes regulatory disclosures about the transaction, delisting, and management changes but does not contain full financial statements or detailed financial performance data. It is a regulatory announcement of significant corporate events rather than a full annual or quarterly report, audit report, or earnings release. Therefore, the filing type corresponds to a Regulatory Filing (RNS), which is the fallback category for such SEC current reports that do not fit other specific categories.
2025-11-21 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.